Coya Therapeutics
COYA
7 hedge funds and large institutions have $4.37M invested in Coya Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.
75% more funds holding
Funds holding: 4 → 7 (+3)
0.2% less ownership
Funds ownership: 11.27% → 11.07% (-0.2%)
15% less capital invested
Capital invested by funds: $5.16M → $4.37M (-$788K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.13K |
| 3 |
TWM
Tradition Wealth Management
Edina,
Minnesota
|
+$3.71K |
| 4 |
GC
Greenlight Capital
New York
|
+$887 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$96 |
Top Sellers
COYA Hedge Fund Activity: Q1 2023 in Review
7 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Coya Therapeutics (COYA) for Q1 2023, worth a combined $4.37M — down 15% from $5.16M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new COYA positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $33.8K.
- 7 institutional investors held Coya Therapeutics (COYA) as of Q1 2023, up from 4 in Q4 2022.
- Funds reported $4.37M of Coya Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 3 funds opened new Coya Therapeutics positions in Q1 2023 and 0 closed out, a net change of +3 holders.
- The largest Coya Therapeutics buyer in Q1 2023 was BlackRock, an estimated $33.8K added.
Based on aggregated 13F filings for Q1 2023.